{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:03:03Z","timestamp":1794747783168,"version":"4.9.1"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-026-02127-8","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:27:04Z","timestamp":1776256024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["DNMT3A in cancer: from epigenetic writer to oncogenic driver"],"prefix":"10.1186","volume":"18","author":[{"given":"Thomas","family":"Dupas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enola","family":"Gautreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josianne","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl J.-M.","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"McGraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2127_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2127_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034366. https:\/\/doi.org\/10.1177\/20503121211034366.","journal-title":"SAGE Open Med"},{"key":"2127_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"C Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9:217\u201322. https:\/\/doi.org\/10.2991\/jegh.k.191008.001.","journal-title":"J Epidemiol Glob Health"},{"key":"2127_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74\u201388. https:\/\/doi.org\/10.1038\/s41580-021-00404-3.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2127_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061303","volume":"14","author":"C Navarro","year":"2022","unstructured":"Navarro C, Ortega \u00c1, Santeliz R, Garrido B, Chac\u00edn M, Galban N, et al. Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches. Pharmaceutics. 2022;14:1303. https:\/\/doi.org\/10.3390\/pharmaceutics14061303.","journal-title":"Pharmaceutics"},{"key":"2127_CR6","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1158\/0008-5472.CAN-20-3730","volume":"81","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yang C. Oncometabolites in cancer: current understanding and challenges. Cancer Res. 2021;81:2820\u20133. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3730.","journal-title":"Cancer Res"},{"key":"2127_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-023-00523-5","volume":"16","author":"T Dupas","year":"2023","unstructured":"Dupas T, Lauzier B, McGraw S. O-GlcNAcylation: the sweet side of epigenetics. Epigenetics Chromatin. 2023;16:49. https:\/\/doi.org\/10.1186\/s13072-023-00523-5.","journal-title":"Epigenetics Chromatin"},{"key":"2127_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-43624-1_7","volume":"945","author":"R Lakshminarasimhan","year":"2016","unstructured":"Lakshminarasimhan R, Liang G. The Role of DNA Methylation in Cancer. Adv Exp Med Biol. 2016;945:151\u201372. https:\/\/doi.org\/10.1007\/978-3-319-43624-1_7.","journal-title":"Adv Exp Med Biol"},{"key":"2127_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrg1748","volume":"7","author":"AP Feinberg","year":"2006","unstructured":"Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21\u201333. https:\/\/doi.org\/10.1038\/nrg1748.","journal-title":"Nat Rev Genet"},{"key":"2127_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE. Epigenetic gene silencing in cancer \u2013 a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107\u201316. https:\/\/doi.org\/10.1038\/nrc1799.","journal-title":"Nat Rev Cancer"},{"key":"2127_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1042\/EBC20190037","volume":"63","author":"K Skvortsova","year":"2019","unstructured":"Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in cancer. Essays Biochem. 2019;63:797\u2013811. https:\/\/doi.org\/10.1042\/EBC20190037.","journal-title":"Essays Biochem"},{"key":"2127_CR12","doi-asserted-by":"publisher","first-page":"175883592312205","DOI":"10.1177\/17588359231220511","volume":"16","author":"F Geissler","year":"2024","unstructured":"Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher EM, Scott CL, et al. The role of aberrant DNA methylation in cancer initiation and clinical impacts. Ther Adv Med Oncol. 2024;16:17588359231220512. https:\/\/doi.org\/10.1177\/17588359231220511.","journal-title":"Ther Adv Med Oncol"},{"key":"2127_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13059-018-1492-3","volume":"19","author":"J Su","year":"2018","unstructured":"Su J, Huang Y-H, Cui X, Wang X, Zhang X, Lei Y, et al. Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol. 2018;19:108. https:\/\/doi.org\/10.1186\/s13059-018-1492-3.","journal-title":"Genome Biol"},{"key":"2127_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Sig Transduct Target Ther. 2019;4:1\u201339. https:\/\/doi.org\/10.1038\/s41392-019-0095-0.","journal-title":"Sig Transduct Target Ther"},{"key":"2127_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0304-3835(01)00748-0","volume":"176","author":"IP Pogribny","year":"2002","unstructured":"Pogribny IP, James SJ. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett. 2002;176:169\u201374. https:\/\/doi.org\/10.1016\/s0304-3835(01)00748-0.","journal-title":"Cancer Lett"},{"key":"2127_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/1535-7163.MCT-16-0588","volume":"16","author":"NJ-M Raynal","year":"2017","unstructured":"Raynal NJ-M, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, et al. Repositioning FDA-approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome. Mol Cancer Ther. 2017;16:397\u2013407. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0588.","journal-title":"Mol Cancer Ther"},{"key":"2127_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000278","volume":"23","author":"EM Da Costa","year":"2017","unstructured":"Da Costa EM, McInnes G, Beaudry A, Raynal NJ-M. DNA methylation\u2013targeted drugs. Cancer J. 2017;23:270. https:\/\/doi.org\/10.1097\/PPO.0000000000000278.","journal-title":"Cancer J"},{"key":"2127_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00280-021-04339-6","volume":"88","author":"M Huot","year":"2021","unstructured":"Huot M, Caron M, Richer C, Djibo R, Najmanovich R, St-Onge P, et al. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. Cancer Chemother Pharmacol. 2021;88:845\u201356. https:\/\/doi.org\/10.1007\/s00280-021-04339-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2127_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/10428194.2016.1228927","volume":"58","author":"B Ball","year":"2017","unstructured":"Ball B, Zeidan A, Gore SD, Prebet T. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2017;58:1022\u201336. https:\/\/doi.org\/10.1080\/10428194.2016.1228927.","journal-title":"Leuk Lymphoma"},{"key":"2127_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35:1873\u201389. https:\/\/doi.org\/10.1038\/s41375-021-01218-0.","journal-title":"Leukemia"},{"key":"2127_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/16078454.2021.1875600","volume":"26","author":"R Xu","year":"2021","unstructured":"Xu R, Li M, Wu P, Deng C, Geng S, Huang X, et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. Hematology. 2021;26:312\u201320. https:\/\/doi.org\/10.1080\/16078454.2021.1875600.","journal-title":"Hematology"},{"key":"2127_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Sig Transduct Target Ther. 2024;9:332. https:\/\/doi.org\/10.1038\/s41392-024-02039-0.","journal-title":"Sig Transduct Target Ther"},{"key":"2127_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/genes8060148","volume":"8","author":"HS Jang","year":"2017","unstructured":"Jang HS, Shin WJ, Lee JE, Do JT. CpG and non-CpG methylation in epigenetic gene regulation and brain function. Genes (Basel). 2017;8:148. https:\/\/doi.org\/10.3390\/genes8060148.","journal-title":"Genes (Basel)"},{"key":"2127_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002389","volume":"7","author":"MJ Ziller","year":"2011","unstructured":"Ziller MJ, M\u00fcller F, Liao J, Zhang Y, Gu H, Bock C, et al. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet. 2011;7:e1002389. https:\/\/doi.org\/10.1371\/journal.pgen.1002389.","journal-title":"PLoS Genet"},{"key":"2127_CR25","doi-asserted-by":"publisher","first-page":"E7526","DOI":"10.1073\/pnas.1703087114","volume":"114","author":"DM Jeziorska","year":"2017","unstructured":"Jeziorska DM, Murray RJS, De Gobbi M, Gaentzsch R, Garrick D, Ayyub H, et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease. Proc Natl Acad Sci. 2017;114:E7526\u201335. https:\/\/doi.org\/10.1073\/pnas.1703087114.","journal-title":"Proc Natl Acad Sci"},{"key":"2127_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/nar\/gku1386","volume":"43","author":"S McGraw","year":"2015","unstructured":"McGraw S, Zhang JX, Farag M, Chan D, Caron M, Konermann C, et al. Transient DNMT1 suppression reveals hidden heritable marks in the genome. Nucleic Acids Res. 2015;43:1485\u201397. https:\/\/doi.org\/10.1093\/nar\/gku1386.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13100-016-0070-z","volume":"7","author":"JL Goodier","year":"2016","unstructured":"Goodier JL. Restricting retrotransposons: a review. Mob DNA. 2016;7:16. https:\/\/doi.org\/10.1186\/s13100-016-0070-z.","journal-title":"Mob DNA"},{"key":"2127_CR28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/15592294.2021.1993607","volume":"17","author":"K Wang","year":"2022","unstructured":"Wang K, Dai R, Xia Y, Tian J, Jiao C, Mikhailova T, et al. Spatiotemporal specificity of correlated DNA methylation and gene expression pairs across different human tissues and stages of brain development. Epigenetics. 2022;17:1110\u201327. https:\/\/doi.org\/10.1080\/15592294.2021.1993607.","journal-title":"Epigenetics"},{"key":"2127_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23\u201338. https:\/\/doi.org\/10.1038\/npp.2012.112.","journal-title":"Neuropsychopharmacology"},{"key":"2127_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01151-0","volume":"13","author":"LM Legault","year":"2021","unstructured":"Legault LM, Doiron K, Breton-Larriv\u00e9e M, Langford-Avelar A, Lemieux A, Caron M, et al. Pre-implantation alcohol exposure induces lasting sex-specific DNA methylation programming errors in the developing forebrain. Clin Epigenetics. 2021;13:164. https:\/\/doi.org\/10.1186\/s13148-021-01151-0.","journal-title":"Clin Epigenetics"},{"key":"2127_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1096\/fj.201901461R","volume":"34","author":"WC Pierre","year":"2020","unstructured":"Pierre WC, Legault L, Londono I, McGraw S, Lodygensky GA. Alteration of the brain methylation landscape following postnatal inflammatory injury in rat pups. FASEB J. 2020;34:432\u201345. https:\/\/doi.org\/10.1096\/fj.201901461R.","journal-title":"FASEB J"},{"key":"2127_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.109014","author":"L-M Legault","year":"2024","unstructured":"Legault L-M, Dupas T, Breton-Larriv\u00e9e M, Filion-Bienvenue F, Lemieux A, Langford-Avelar A, et al. Sex-specific DNA methylation and gene expression changes in mouse placentas after early preimplantation alcohol exposure. Environ Int. 2024. https:\/\/doi.org\/10.1016\/j.envint.2024.109014.","journal-title":"Environ Int"},{"key":"2127_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19:81\u201392. https:\/\/doi.org\/10.1038\/nrg.2017.80.","journal-title":"Nat Rev Genet"},{"key":"2127_CR34","doi-asserted-by":"publisher","first-page":"gkaf130","DOI":"10.1093\/nar\/gkaf130","volume":"53","author":"E Elder","year":"2025","unstructured":"Elder E, Lemieux A, Legault L-M, Caron M, Bertrand-Lehouillier V, Dupas T, et al. Rescuing DNMT1 fails to fully reverse the molecular and functional repercussions of its loss in mouse embryonic stem cells. Nucleic Acids Res. 2025;53:gkaf130. https:\/\/doi.org\/10.1093\/nar\/gkaf130.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR35","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/sj.onc.1210855","volume":"27","author":"M Achour","year":"2008","unstructured":"Achour M, Jacq X, Rond\u00e9 P, Alhosin M, Charlot C, Chataigneau T, et al. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene. 2008;27:2187\u201397. https:\/\/doi.org\/10.1038\/sj.onc.1210855.","journal-title":"Oncogene"},{"key":"2127_CR36","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1126\/science.1147939","volume":"317","author":"M Bostick","year":"2007","unstructured":"Bostick M, Kim JK, Est\u00e8ve P-O, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317:1760\u20134. https:\/\/doi.org\/10.1126\/science.1147939.","journal-title":"Science"},{"key":"2127_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.1195380","volume":"331","author":"J Song","year":"2011","unstructured":"Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science. 2011;331:1036\u201340. https:\/\/doi.org\/10.1126\/science.1195380.","journal-title":"Science"},{"key":"2127_CR38","doi-asserted-by":"publisher","first-page":"19466","DOI":"10.1074\/jbc.RA118.004612","volume":"293","author":"O Yarychkivska","year":"2018","unstructured":"Yarychkivska O, Shahabuddin Z, Comfort N, Boulard M, Bestor TH. BAH domains and a histone-like motif in DNA methyltransferase 1 (DNMT1) regulate de novo and maintenance methylation in vivo. J Biol Chem. 2018;293:19466\u201375. https:\/\/doi.org\/10.1074\/jbc.RA118.004612.","journal-title":"J Biol Chem"},{"key":"2127_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.bbrc.2019.06.060","volume":"516","author":"T Jimenji","year":"2019","unstructured":"Jimenji T, Matsumura R, Kori S, Arita K. Structure of PCNA in complex with DNMT1 PIP box reveals the basis for the molecular mechanism of the interaction. Biochem Biophys Res Commun. 2019;516:578\u201383. https:\/\/doi.org\/10.1016\/j.bbrc.2019.06.060.","journal-title":"Biochem Biophys Res Commun"},{"key":"2127_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/77023","volume":"25","author":"MR Rountree","year":"2000","unstructured":"Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet. 2000;25:269\u201377. https:\/\/doi.org\/10.1038\/77023.","journal-title":"Nat Genet"},{"key":"2127_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247\u201357. https:\/\/doi.org\/10.1016\/S0092-8674(00)81656-6.","journal-title":"Cell"},{"key":"2127_CR42","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1128\/MCB.00899-07","volume":"27","author":"S Takebayashi","year":"2007","unstructured":"Takebayashi S, Tamura T, Matsuoka C, Okano M. Major and essential role for the DNA methylation mark in Mouse embryogenesis and stable association of DNMT1 with newly replicated regions. Mol Cell Biol. 2007;27:8243\u201358. https:\/\/doi.org\/10.1128\/MCB.00899-07.","journal-title":"Mol Cell Biol"},{"key":"2127_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.1120976","volume":"311","author":"MG Goll","year":"2006","unstructured":"Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh C-L, Zhang X, et al. Methylation of tRNA Asp by the DNA Methyltransferase Homolog Dnmt2. Science. 2006;311:395\u20138. https:\/\/doi.org\/10.1126\/science.1120976.","journal-title":"Science"},{"key":"2127_CR44","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1261\/rna.970408","volume":"14","author":"TP Jurkowski","year":"2008","unstructured":"Jurkowski TP, Meusburger M, Phalke S, Helm M, Nellen W, Reuter G, et al. Human DNMT2 methylates tRNA Asp molecules using a DNA methyltransferase-like catalytic mechanism. RNA. 2008;14:1663\u201370. https:\/\/doi.org\/10.1261\/rna.970408.","journal-title":"RNA"},{"key":"2127_CR45","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1101\/gad.586710","volume":"24","author":"M Schaefer","year":"2010","unstructured":"Schaefer M, Pollex T, Hanna K, Tuorto F, Meusburger M, Helm M, et al. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes Dev. 2010;24:1590\u20135. https:\/\/doi.org\/10.1101\/gad.586710.","journal-title":"Genes Dev"},{"key":"2127_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae012","volume":"6","author":"AM A\u00f1azco-Guenkova","year":"2024","unstructured":"A\u00f1azco-Guenkova AM, Miguel-L\u00f3pez B, Monteagudo-Garc\u00eda \u00d3, Garc\u00eda-V\u00edlchez R, Blanco S. The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues. NAR Cancer. 2024;6:zcae012. https:\/\/doi.org\/10.1093\/narcan\/zcae012.","journal-title":"NAR Cancer"},{"key":"2127_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.21451\/1984-3143-AR2019-0062","volume":"16","author":"M Breton-Larriv\u00e9e","year":"2019","unstructured":"Breton-Larriv\u00e9e M, Elder E, McGraw S. DNA methylation, environmental exposures and early embryo development. Anim Reprod. 2019;16:465\u201374. https:\/\/doi.org\/10.21451\/1984-3143-AR2019-0062.","journal-title":"Anim Reprod"},{"key":"2127_CR48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109475118","volume":"118","author":"M Kinoshita","year":"2021","unstructured":"Kinoshita M, Li MA, Barber M, Mansfield W, Dietmann S, Smith A. Disabling de novo DNA methylation in embryonic stem cells allows an illegitimate fate trajectory. Proc Natl Acad Sci U S A. 2021;118:e2109475118. https:\/\/doi.org\/10.1073\/pnas.2109475118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2127_CR49","doi-asserted-by":"publisher","first-page":"9048","DOI":"10.1128\/MCB.24.20.9048-9058.2004","volume":"24","author":"T Chen","year":"2004","unstructured":"Chen T, Tsujimoto N, Li E. The PWWP Domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at Pericentric Heterochromatin. Mol Cell Biol. 2004;24:9048\u201358. https:\/\/doi.org\/10.1128\/MCB.24.20.9048-9058.2004.","journal-title":"Mol Cell Biol"},{"key":"2127_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/ng.3258","volume":"47","author":"J Liao","year":"2015","unstructured":"Liao J, Karnik R, Gu H, Ziller MJ, Clement K, Tsankov AM, et al. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nat Genet. 2015;47:469\u201378. https:\/\/doi.org\/10.1038\/ng.3258.","journal-title":"Nat Genet"},{"key":"2127_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.abb.2010.03.007","volume":"498","author":"MM Purdy","year":"2010","unstructured":"Purdy MM, Holz-Schietinger C, Reich NO. Identification of a second DNA binding site in human DNA methyltransferase 3A by substrate inhibition and domain deletion. Arch Biochem Biophys. 2010;498:13\u201322. https:\/\/doi.org\/10.1016\/j.abb.2010.03.007.","journal-title":"Arch Biochem Biophys"},{"key":"2127_CR52","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.stem.2014.06.018","volume":"15","author":"GA Challen","year":"2014","unstructured":"Challen GA, Sun D, Mayle A, Jeong M, Luo M, Rodriguez B, et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell. 2014;15:350\u201364. https:\/\/doi.org\/10.1016\/j.stem.2014.06.018.","journal-title":"Cell Stem Cell"},{"key":"2127_CR53","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1016\/j.jmb.2019.09.006","volume":"431","author":"M Dukatz","year":"2019","unstructured":"Dukatz M, Holzer K, Choudalakis M, Emperle M, Lungu C, Bashtrykov P, et al. H3K36me2\/3 Binding and DNA Binding of the DNA Methyltransferase DNMT3A PWWP domain both contribute to its chromatin interaction. J Mol Biol. 2019;431:5063\u201374. https:\/\/doi.org\/10.1016\/j.jmb.2019.09.006.","journal-title":"J Mol Biol"},{"key":"2127_CR54","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1007\/s00018-019-03144-y","volume":"76","author":"J Li","year":"2019","unstructured":"Li J, Ahn JH, Wang GG. Understanding histone H3 lysine 36 methylation and its deregulation in disease. Cell Mol Life Sci. 2019;76:2899\u2013916. https:\/\/doi.org\/10.1007\/s00018-019-03144-y.","journal-title":"Cell Mol Life Sci"},{"key":"2127_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-019-1534-3","volume":"573","author":"DN Weinberg","year":"2019","unstructured":"Weinberg DN, Papillon-Cavanagh S, Chen H, Yue Y, Chen X, Rajagopalan KN, et al. The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature. 2019;573:281\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1534-3.","journal-title":"Nature"},{"key":"2127_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32141-2","volume":"13","author":"S Yano","year":"2022","unstructured":"Yano S, Ishiuchi T, Abe S, Namekawa SH, Huang G, Ogawa Y, et al. Histone H3K36me2 and H3K36me3 form a chromatin platform essential for DNMT3A-dependent DNA methylation in mouse oocytes. Nat Commun. 2022;13:4440. https:\/\/doi.org\/10.1038\/s41467-022-32141-2.","journal-title":"Nat Commun"},{"key":"2127_CR57","doi-asserted-by":"publisher","first-page":"27816","DOI":"10.1074\/jbc.M400181200","volume":"279","author":"I Suetake","year":"2004","unstructured":"Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction*. J Biol Chem. 2004;279:27816\u201323. https:\/\/doi.org\/10.1074\/jbc.M400181200.","journal-title":"J Biol Chem"},{"key":"2127_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17109-4","volume":"11","author":"L Gao","year":"2020","unstructured":"Gao L, Emperle M, Guo Y, Grimm SA, Ren W, Adam S, et al. Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms. Nat Commun. 2020;11:3355. https:\/\/doi.org\/10.1038\/s41467-020-17109-4.","journal-title":"Nat Commun"},{"key":"2127_CR59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25477","volume":"554","author":"Z-M Zhang","year":"2018","unstructured":"Zhang Z-M, Lu R, Wang P, Yu Y, Chen D, Gao L, et al. Structural basis for DNMT3A-mediated de novo DNA methylation. Nature. 2018;554:387\u201391. https:\/\/doi.org\/10.1038\/nature25477.","journal-title":"Nature"},{"key":"2127_CR60","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1242\/dev.129.8.1983","volume":"129","author":"K Hata","year":"2002","unstructured":"Hata K, Okano M, Lei H, Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development. 2002;129:1983\u201393. https:\/\/doi.org\/10.1242\/dev.129.8.1983.","journal-title":"Development"},{"key":"2127_CR61","doi-asserted-by":"publisher","first-page":"16916","DOI":"10.1073\/pnas.262443999","volume":"99","author":"F Ch\u00e9din","year":"2002","unstructured":"Ch\u00e9din F, Lieber MR, Hsieh C-L. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci. 2002;99:16916\u201321. https:\/\/doi.org\/10.1073\/pnas.262443999.","journal-title":"Proc Natl Acad Sci"},{"key":"2127_CR62","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1126\/science.1065848","volume":"294","author":"D Bourc\u2019his","year":"2001","unstructured":"Bourc\u2019his D, Xu G-L, Lin C-S, Bollman B, Bestor TH. Dnmt3L and the establishment of maternal genomic imprints. Science. 2001;294:2536\u20139. https:\/\/doi.org\/10.1126\/science.1065848.","journal-title":"Science"},{"key":"2127_CR63","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1093\/nar\/gkq147","volume":"38","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Jurkowska R, Soeroes S, Rajavelu A, Dhayalan A, Bock I, et al. Chromatin methylation activity of Dnmt3a and Dnmt3a\/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res. 2010;38:4246\u201353. https:\/\/doi.org\/10.1093\/nar\/gkq147.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/gm346","volume":"4","author":"D Balasubramanian","year":"2012","unstructured":"Balasubramanian D, Akhtar-Zaidi B, Song L, Bartels CF, Veigl M, Beard L, et al. H3K4me3 inversely correlates with DNA methylation at a large class of non-CpG-island-containing start sites. Genome Med. 2012;4:47. https:\/\/doi.org\/10.1186\/gm346.","journal-title":"Genome Med"},{"key":"2127_CR65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbrc.2022.06.036","volume":"619","author":"K Boyko","year":"2022","unstructured":"Boyko K, Arkova O, Nikolaeva A, Popov VO, Georgiev P, Bonchuk A. Structure of the DNMT3B ADD domain suggests the absence of a DNMT3A-like autoinhibitory mechanism. Biochem Biophys Res Commun. 2022;619:124\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2022.06.036.","journal-title":"Biochem Biophys Res Commun"},{"key":"2127_CR66","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jmb.2006.01.035","volume":"357","author":"H Gowher","year":"2006","unstructured":"Gowher H, Loutchanwoot P, Vorobjeva O, Handa V, Jurkowska RZ, Jurkowski TP, et al. Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. J Mol Biol. 2006;357:928\u201341. https:\/\/doi.org\/10.1016\/j.jmb.2006.01.035.","journal-title":"J Mol Biol"},{"key":"2127_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01537-x","volume":"8","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang Y, Wang C, Wang X. TET (Ten-eleven translocation) family proteins: structure, biological functions and applications. Sig Transduct Target Ther. 2023;8:1\u201320. https:\/\/doi.org\/10.1038\/s41392-023-01537-x.","journal-title":"Sig Transduct Target Ther"},{"key":"2127_CR68","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","volume":"30","author":"KD Rasmussen","year":"2016","unstructured":"Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30:733\u201350. https:\/\/doi.org\/10.1101\/gad.276568.115.","journal-title":"Genes Dev"},{"key":"2127_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13073-015-0134-6","volume":"7","author":"L Scourzic","year":"2015","unstructured":"Scourzic L, Mouly E, Bernard OA. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 2015;7:9\u20139. https:\/\/doi.org\/10.1186\/s13073-015-0134-6.","journal-title":"Genome Med"},{"key":"2127_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082123","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yang C, Wu C, Cui W, Wang L. DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy. Cancers. 2020;12:2123. https:\/\/doi.org\/10.3390\/cancers12082123.","journal-title":"Cancers"},{"key":"2127_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-9967-2_1","volume":"754","author":"B Jin","year":"2013","unstructured":"Jin B, Robertson KD. DNA methyltransferases (DNMTs), DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3\u201329. https:\/\/doi.org\/10.1007\/978-1-4419-9967-2_1.","journal-title":"Adv Exp Med Biol"},{"key":"2127_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00080","author":"D Subramaniam","year":"2014","unstructured":"Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014. https:\/\/doi.org\/10.3389\/fonc.2014.00080.","journal-title":"Front Oncol"},{"key":"2127_CR73","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11060-025-05032-x","volume":"173","author":"S Sufiyan","year":"2025","unstructured":"Sufiyan S, Salam H, Ilyas S, Amin W, Arshad F, Fatima K, et al. Prognostic implications of DNA methylation machinery (DNMTs and TETs) expression in gliomas: correlations with tumor grading and patient survival. J Neurooncol. 2025;173:667\u201382. https:\/\/doi.org\/10.1007\/s11060-025-05032-x.","journal-title":"J Neurooncol"},{"key":"2127_CR74","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.humpath.2010.01.011","volume":"41","author":"MdM Rahman","year":"2010","unstructured":"Rahman MdM, Qian ZR, Lu Wang E, Yoshimoto K, Nakasono M, Sultana R, et al. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2010;41:1069\u201378. https:\/\/doi.org\/10.1016\/j.humpath.2010.01.011.","journal-title":"Hum Pathol"},{"key":"2127_CR75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1756-9966-32-86","volume":"32","author":"J Gao","year":"2013","unstructured":"Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res. 2013;32:86. https:\/\/doi.org\/10.1186\/1756-9966-32-86.","journal-title":"J Exp Clin Cancer Res"},{"key":"2127_CR76","first-page":"65","volume":"20","author":"B-K Oh","year":"2007","unstructured":"Oh B-K, Kim H, Park H-J, Shim Y-H, Choi J, Park C, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med. 2007;20:65\u201373.","journal-title":"Int J Mol Med"},{"key":"2127_CR77","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.3748\/wjg.v20.i25.8201","volume":"20","author":"X-Y Cao","year":"2014","unstructured":"Cao X-Y, Ma H-X, Shang Y-H, Jin M-S, Kong F, Jia Z-F. DNA methyltransferase3a expression is an independent poor prognostic indicator in gastric cancer. World J Gastroenterol. 2014;20:8201\u20138. https:\/\/doi.org\/10.3748\/wjg.v20.i25.8201.","journal-title":"World J Gastroenterol"},{"key":"2127_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81971-5","volume":"11","author":"J Cui","year":"2021","unstructured":"Cui J, Zheng L, Zhang Y, Xue M. Bioinformatics analysis of DNMT1 expression and its role in head and neck squamous cell carcinoma prognosis. Sci Rep. 2021;11:2267. https:\/\/doi.org\/10.1038\/s41598-021-81971-5.","journal-title":"Sci Rep"},{"key":"2127_CR79","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK. DNMT1: a key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198\u2013213. https:\/\/doi.org\/10.1016\/j.semcancer.2020.05.010.","journal-title":"Semin Cancer Biol"},{"key":"2127_CR80","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2:1002\u201317. https:\/\/doi.org\/10.1038\/s43018-021-00249-x.","journal-title":"Nat Cancer"},{"key":"2127_CR81","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s43018-021-00271-z","volume":"2","author":"P Mehdipour","year":"2021","unstructured":"Mehdipour P, Chen R, De Carvalho DD. The next generation of DNMT inhibitors. Nat Cancer. 2021;2:1000\u20131. https:\/\/doi.org\/10.1038\/s43018-021-00271-z.","journal-title":"Nat Cancer"},{"key":"2127_CR82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3892\/br.2012.34","volume":"1","author":"M He","year":"2013","unstructured":"He M, Fan J, Jiang R, Tang W-X, Wang Z-W. Expression of DNMTs and MBD2 in GIST. Biomed Rep. 2013;1:223\u20137. https:\/\/doi.org\/10.3892\/br.2012.34.","journal-title":"Biomed Rep"},{"key":"2127_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204950","volume":"15","author":"E Papakonstantinou","year":"2023","unstructured":"Papakonstantinou E, Pappa I, Androutsopoulos G, Adonakis G, Maroulis I, Tzelepi V. Comprehensive analysis of DNA methyltransferases expression in primary and relapsed ovarian carcinoma. Cancers Basel. 2023;15:4950. https:\/\/doi.org\/10.3390\/cancers15204950.","journal-title":"Cancers Basel"},{"key":"2127_CR84","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10495-022-01779-0","volume":"28","author":"J Adamczyk-Grochala","year":"2023","unstructured":"Adamczyk-Grochala J, Bloniarz D, Zielinska K, Lewinska A, Wnuk M. DNMT2\/TRDMT1 gene knockout compromises doxorubicin-induced unfolded protein response and sensitizes cancer cells to ER stress-induced apoptosis. Apoptosis. 2023;28:166\u201385. https:\/\/doi.org\/10.1007\/s10495-022-01779-0.","journal-title":"Apoptosis"},{"key":"2127_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.biochi.2015.02.022","volume":"112","author":"W Elhardt","year":"2015","unstructured":"Elhardt W, Shanmugam R, Jurkowski TP, Jeltsch A. Somatic cancer mutations in the DNMT2 tRNA methyltransferase alter its catalytic properties. Biochimie. 2015;112:66\u201372. https:\/\/doi.org\/10.1016\/j.biochi.2015.02.022.","journal-title":"Biochimie"},{"key":"2127_CR86","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-09-3338","volume":"16","author":"K Minami","year":"2010","unstructured":"Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, et al. DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma. Clin Cancer Res. 2010;16:2751\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3338.","journal-title":"Clin Cancer Res"},{"key":"2127_CR87","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pathol.2019.10.006","volume":"52","author":"V Tzelepi","year":"2020","unstructured":"Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, et al. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology. 2020;52:218\u201327. https:\/\/doi.org\/10.1016\/j.pathol.2019.10.006.","journal-title":"Pathology"},{"key":"2127_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04939-9","volume":"22","author":"X Yan","year":"2024","unstructured":"Yan X, Qi Y, Yao X, Zhou N, Ye X, Chen X. DNMT3L inhibits hepatocellular carcinoma progression through DNA methylation of CDO1: insights from big data to basic research. J Transl Med. 2024;22:128. https:\/\/doi.org\/10.1186\/s12967-024-04939-9.","journal-title":"J Transl Med"},{"key":"2127_CR89","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1158\/1541-7786.MCR-21-0887","volume":"20","author":"JY So","year":"2022","unstructured":"So JY, Yang HH, Park WY, Skrypek N, Ishii H, Chen JM, et al. DNA methyltransferase 3B\u2013mediated intratumoral heterogeneity and therapeutic targeting in breast cancer recurrence and metastasis. Mol Cancer Res. 2022;20:1674\u201385. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0887.","journal-title":"Mol Cancer Res"},{"key":"2127_CR90","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1158\/0008-5472.CAN-19-3339","volume":"80","author":"JY So","year":"2020","unstructured":"So JY, Skrypek N, Yang HH, Merchant AS, Nelson GW, Chen W-D, et al. Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization. Cancer Res. 2020;80:2612\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3339.","journal-title":"Cancer Res"},{"key":"2127_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103191","volume":"63","author":"K Lopusna","year":"2021","unstructured":"Lopusna K, Nowialis P, Opavska J, Abraham A, Riva A, Opavsky R. Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling. EBioMedicine. 2021;63:103191. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103191.","journal-title":"EBioMedicine"},{"key":"2127_CR92","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita, McLaren K, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52:D1210\u20137. https:\/\/doi.org\/10.1093\/nar\/gkad986.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR93","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","unstructured":"AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0151.","journal-title":"Cancer Discov"},{"key":"2127_CR94","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360. https:\/\/doi.org\/10.1093\/nar\/gkz430.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR95","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature19768","volume":"538","author":"F Blokzijl","year":"2016","unstructured":"Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature. 2016;538:260\u20134. https:\/\/doi.org\/10.1038\/nature19768.","journal-title":"Nature"},{"key":"2127_CR96","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw0726","volume":"364","author":"K Yizhak","year":"2019","unstructured":"Yizhak K, Aguet F, Kim J, Hess JM, K\u00fcbler K, Grimsby J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science. 2019;364:eaaw0726. https:\/\/doi.org\/10.1126\/science.aaw0726.","journal-title":"Science"},{"key":"2127_CR97","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.aau3879","volume":"362","author":"I Martincorena","year":"2018","unstructured":"Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362:911\u20137. https:\/\/doi.org\/10.1126\/science.aau3879.","journal-title":"Science"},{"key":"2127_CR98","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","volume":"574","author":"H Lee-Six","year":"2019","unstructured":"Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574:532\u20137. https:\/\/doi.org\/10.1038\/s41586-019-1672-7.","journal-title":"Nature"},{"key":"2127_CR99","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","volume":"101","author":"R Acuna-Hidalgo","year":"2017","unstructured":"Acuna-Hidalgo R, Sengul H, Steehouwer M, van de Vorst M, Vermeulen SH, Kiemeney LALM, et al. Ultra-sensitive sequencing identifies high prevalence of Clonal Hematopoiesis-Associated mutations throughout adult life. Am J Hum Genet. 2017;101:50\u201364. https:\/\/doi.org\/10.1016\/j.ajhg.2017.05.013.","journal-title":"Am J Hum Genet"},{"key":"2127_CR100","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1409405.","journal-title":"N Engl J Med"},{"key":"2127_CR101","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related Clonal Hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1408617.","journal-title":"N Engl J Med"},{"key":"2127_CR102","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472\u20138. https:\/\/doi.org\/10.1038\/nm.3733.","journal-title":"Nat Med"},{"key":"2127_CR103","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a006251","volume":"9","author":"EA Goldman","year":"2023","unstructured":"Goldman EA, Spellman PT, Agarwal A. Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation. Cold Spring Harb Mol Case Stud. 2023;9:a006251. https:\/\/doi.org\/10.1101\/mcs.a006251.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"2127_CR104","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1701719.","journal-title":"N Engl J Med"},{"key":"2127_CR105","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41586-023-05857-4","volume":"616","author":"WJ Wong","year":"2023","unstructured":"Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, et al. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023;616:747\u201354. https:\/\/doi.org\/10.1038\/s41586-023-05857-4.","journal-title":"Nature"},{"key":"2127_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","volume":"4","author":"L Dorsheimer","year":"2019","unstructured":"Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to Clonal Hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25\u201333. https:\/\/doi.org\/10.1001\/jamacardio.2018.3965.","journal-title":"JAMA Cardiol"},{"key":"2127_CR107","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.stem.2024.05.010","volume":"31","author":"NA Jakobsen","year":"2024","unstructured":"Jakobsen NA, Turkalj S, Zeng AGX, Stoilova B, Metzner M, Rahmig S, et al. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell Stem Cell. 2024;31:1127-1144.e17. https:\/\/doi.org\/10.1016\/j.stem.2024.05.010.","journal-title":"Cell Stem Cell"},{"key":"2127_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33093-3","volume":"13","author":"MDM Uddin","year":"2022","unstructured":"Uddin MDM, Nguyen NQH, Yu B, Brody JA, Pampana A, Nakao T, et al. Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease. Nat Commun. 2022;13:5350. https:\/\/doi.org\/10.1038\/s41467-022-33093-3.","journal-title":"Nat Commun"},{"key":"2127_CR109","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17:13\u201327. https:\/\/doi.org\/10.1016\/j.ccr.2009.11.020.","journal-title":"Cancer Cell"},{"key":"2127_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62005-4","volume":"16","author":"F Marchi","year":"2025","unstructured":"Marchi F, Shastri VM, Marrero RJ, Nguyen NHK, \u00d6ttl A, Schade A-K, et al. Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia. Nat Commun. 2025;16:6961. https:\/\/doi.org\/10.1038\/s41467-025-62005-4.","journal-title":"Nat Commun"},{"key":"2127_CR111","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2009-07-233858","volume":"115","author":"TA Paul","year":"2010","unstructured":"Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood. 2010;115:3098\u2013108. https:\/\/doi.org\/10.1182\/blood-2009-07-233858.","journal-title":"Blood"},{"key":"2127_CR112","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2010.222","volume":"25","author":"T-C Lin","year":"2011","unstructured":"Lin T-C, Hou H-A, Chou W-C, Ou D-L, Yu S-L, Tien H-F, et al. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia. 2011;25:32\u201340. https:\/\/doi.org\/10.1038\/leu.2010.222.","journal-title":"Leukemia"},{"key":"2127_CR113","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3390\/ijms20184576","volume":"20","author":"X Yang","year":"2019","unstructured":"Yang X, Wong MPM, Ng RK. Aberrant DNA methylation in acute myeloid Leukemia and its clinical implications. Int J Mol Sci. 2019;20:4576. https:\/\/doi.org\/10.3390\/ijms20184576.","journal-title":"Int J Mol Sci"},{"key":"2127_CR114","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005.","journal-title":"Blood Rev"},{"key":"2127_CR115","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in Acute Myeloid Leukemia. N Engl J Med. 2010;363:2424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1005143.","journal-title":"N Engl J Med"},{"key":"2127_CR116","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2013-02-483487","volume":"122","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood. 2013;122:4086\u20139. https:\/\/doi.org\/10.1182\/blood-2013-02-483487.","journal-title":"Blood"},{"key":"2127_CR117","doi-asserted-by":"publisher","first-page":"41479","DOI":"10.1074\/jbc.M111.284687","volume":"286","author":"C Holz-Schietinger","year":"2011","unstructured":"Holz-Schietinger C, Matje DM, Harrison MF, Reich NO. Oligomerization of DNMT3A controls the mechanism of de Novo DNA methylation. J Biol Chem. 2011;286:41479\u201388. https:\/\/doi.org\/10.1074\/jbc.M111.284687.","journal-title":"J Biol Chem"},{"key":"2127_CR118","doi-asserted-by":"publisher","first-page":"30941","DOI":"10.1074\/jbc.M112.366625","volume":"287","author":"C Holz-Schietinger","year":"2012","unstructured":"Holz-Schietinger C, Matje DM, Reich NO. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem. 2012;287:30941\u201351. https:\/\/doi.org\/10.1074\/jbc.M112.366625.","journal-title":"J Biol Chem"},{"key":"2127_CR119","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2013.08.056","volume":"155","author":"F Neri","year":"2013","unstructured":"Neri F, Krepelova A, Incarnato D, Maldotti M, Parlato C, Galvagni F, et al. Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs. Cell. 2013;155:121\u201334. https:\/\/doi.org\/10.1016\/j.cell.2013.08.056.","journal-title":"Cell"},{"key":"2127_CR120","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","volume":"25","author":"DA Russler-Germain","year":"2014","unstructured":"Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25:442\u201354. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.010.","journal-title":"Cancer Cell"},{"key":"2127_CR121","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8598","volume":"10","author":"Y Li","year":"2024","unstructured":"Li Y, Abel HJ, Cai M, LaValle TA, Yin T, Helton NM, et al. Rapid and accurate remethylation of DNA in Dnmt3a-deficient hematopoietic cells with restoration of DNMT3A activity. Sci Adv. 2024;10:eadk8598. https:\/\/doi.org\/10.1126\/sciadv.adk8598.","journal-title":"Sci Adv"},{"key":"2127_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31635-8","volume":"8","author":"M Emperle","year":"2018","unstructured":"Emperle M, Dukatz M, Kunert S, Holzer K, Rajavelu A, Jurkowska RZ, et al. The DNMT3A R882H mutation does not cause dominant negative effects in purified mixed DNMT3A\/R882H complexes. Sci Rep. 2018;8:13242. https:\/\/doi.org\/10.1038\/s41598-018-31635-8.","journal-title":"Sci Rep"},{"key":"2127_CR123","doi-asserted-by":"publisher","first-page":"16966","DOI":"10.1074\/jbc.RA119.010126","volume":"294","author":"T-V Nguyen","year":"2019","unstructured":"Nguyen T-V, Yao S, Wang Y, Rolfe A, Selvaraj A, Darman R, et al. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity. J Biol Chem. 2019;294:16966\u201377. https:\/\/doi.org\/10.1074\/jbc.RA119.010126.","journal-title":"J Biol Chem"},{"key":"2127_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167482","volume":"434","author":"A Mack","year":"2022","unstructured":"Mack A, Emperle M, Schnee P, Adam S, Pleiss J, Bashtrykov P, et al. Preferential self-interaction of DNA methyltransferase DNMT3A subunits containing the R882H cancer mutation leads to dominant changes of flanking sequence preferences. J Mol Biol. 2022;434:167482. https:\/\/doi.org\/10.1016\/j.jmb.2022.167482.","journal-title":"J Mol Biol"},{"key":"2127_CR125","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1093\/nar\/gky168","volume":"46","author":"M Emperle","year":"2018","unstructured":"Emperle M, Rajavelu A, Kunert S, Arimondo PB, Reinhardt R, Jurkowska RZ, et al. The DNMT3A R882H mutant displays altered flanking sequence preferences. Nucleic Acids Res. 2018;46:3130\u20139. https:\/\/doi.org\/10.1093\/nar\/gky168.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16213-9","volume":"11","author":"H Anteneh","year":"2020","unstructured":"Anteneh H, Fang J, Song J. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation. Nat Commun. 2020;11:2294. https:\/\/doi.org\/10.1038\/s41467-020-16213-9.","journal-title":"Nat Commun"},{"key":"2127_CR127","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1073\/pnas.1400150111","volume":"111","author":"J Xu","year":"2014","unstructured":"Xu J, Wang Y-Y, Dai Y-J, Zhang W, Zhang W-N, Xiong S-M, et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression\/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A. 2014;111:2620\u20135. https:\/\/doi.org\/10.1073\/pnas.1400150111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2127_CR128","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccell.2016.05.008","volume":"30","author":"R Lu","year":"2016","unstructured":"Lu R, Wang P, Parton T, Zhou Y, Chrysovergis K, Rockowitz S, et al. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development. Cancer Cell. 2016;30:92\u2013107. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.008.","journal-title":"Cancer Cell"},{"key":"2127_CR129","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/ng.788","volume":"43","author":"X-J Yan","year":"2011","unstructured":"Yan X-J, Xu J, Gu Z-H, Pan C-M, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43:309\u201315. https:\/\/doi.org\/10.1038\/ng.788.","journal-title":"Nat Genet"},{"key":"2127_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.678368","author":"M Chen","year":"2021","unstructured":"Chen M, Qu Y, Yue P, Yan X. The prognostic value and function of HOXB5 in Acute Myeloid Leukemia. Front Genet. 2021. https:\/\/doi.org\/10.3389\/fgene.2021.678368.","journal-title":"Front Genet"},{"key":"2127_CR131","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jare.2019.05.006","volume":"20","author":"\u00c1 Nagy","year":"2019","unstructured":"Nagy \u00c1, \u0150sz \u00c1, Budczies J, Krizs\u00e1n S, Szombath G, Demeter J, et al. Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival. J Adv Res. 2019;20:105\u201316. https:\/\/doi.org\/10.1016\/j.jare.2019.05.006.","journal-title":"J Adv Res"},{"key":"2127_CR132","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1200\/JCO.2014.59.2022","volume":"33","author":"RE Gale","year":"2015","unstructured":"Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, et al. Simpson\u2019s Paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33:2072\u201383. https:\/\/doi.org\/10.1200\/JCO.2014.59.2022.","journal-title":"J Clin Oncol"},{"key":"2127_CR133","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrc3895","volume":"15","author":"L Yang","year":"2015","unstructured":"Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15:152\u201365. https:\/\/doi.org\/10.1038\/nrc3895.","journal-title":"Nat Rev Cancer"},{"key":"2127_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00978-1","volume":"20","author":"X Chu","year":"2022","unstructured":"Chu X, Zhong L, Dan W, Wang X, Zhang Z, Liu Z, et al. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2\/NQO1 pathway. Cell Commun Signal. 2022;20:168. https:\/\/doi.org\/10.1186\/s12964-022-00978-1.","journal-title":"Cell Commun Signal"},{"key":"2127_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-0191-6","volume":"9","author":"R Bera","year":"2020","unstructured":"Bera R, Chiu M-C, Huang Y-J, Huang G, Lee Y-S, Shih L-Y. DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells. Oncogenesis. 2020;9:1\u201316. https:\/\/doi.org\/10.1038\/s41389-020-0191-6.","journal-title":"Oncogenesis"},{"key":"2127_CR136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121657","volume":"134","author":"Y-J Dai","year":"2019","unstructured":"Dai Y-J, Hu F, He S-Y, Tian X-P, Li H-H, Qin Z-Y, et al. A distinct metabolic signature in DNMT3A-mutated leukemia. Blood. 2019;134:1426. https:\/\/doi.org\/10.1182\/blood-2019-121657.","journal-title":"Blood"},{"key":"2127_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7497\/j.issn.2095-3941.2014.01.001","volume":"11","author":"LM Phan","year":"2014","unstructured":"Phan LM, Yeung S-CJ, Lee M-H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014;11:1\u201319. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2014.01.001.","journal-title":"Cancer Biol Med"},{"key":"2127_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04323-z","volume":"21","author":"X Yang","year":"2023","unstructured":"Yang X, Wang X, Yang Y, Li Z, Chen Y, Shang S, et al. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming. J Transl Med. 2023;21:481. https:\/\/doi.org\/10.1186\/s12967-023-04323-z.","journal-title":"J Transl Med"},{"key":"2127_CR139","doi-asserted-by":"publisher","first-page":"30395","DOI":"10.18632\/oncotarget.16449","volume":"8","author":"L Yang","year":"2017","unstructured":"Yang L, Liu Y, Zhang N, Ding X, Zhang W, Shen K, et al. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs. Oncotarget. 2017;8:30395\u2013409. https:\/\/doi.org\/10.18632\/oncotarget.16449.","journal-title":"Oncotarget"},{"key":"2127_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110626","volume":"105","author":"X Chu","year":"2023","unstructured":"Chu X, Zhong L, Dan W, Wang X, Zhang Z, Liu Z, et al. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2\/NQO1 axis. Cell Signal. 2023;105:110626. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110626.","journal-title":"Cell Signal"},{"key":"2127_CR141","doi-asserted-by":"publisher","first-page":"8727","DOI":"10.1182\/blood-2022-170287","volume":"140","author":"Y Li","year":"2022","unstructured":"Li Y, Xu Z, Day RB, Mi Y, Erdmann-Gilmore P, Townsend RR, et al. The protein interactome of DNMT3A, and altered interactions caused by missense mutations associated with AML and\/or the DNMT3A overgrowth syndrome. Blood. 2022;140:8727\u20138. https:\/\/doi.org\/10.1182\/blood-2022-170287.","journal-title":"Blood"},{"key":"2127_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/biom11060781","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang Y, Dai Y, Yang X, Wu S, Wang Y. DNMT3A mutation-induced CDK1 overexpression promotes leukemogenesis by modulating the interaction between EZH2 and DNMT3A. Biomolecules. 2021;11:781. https:\/\/doi.org\/10.3390\/biom11060781.","journal-title":"Biomolecules"},{"key":"2127_CR143","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192\u2013203. https:\/\/doi.org\/10.1038\/s12276-020-0384-2.","journal-title":"Exp Mol Med"},{"key":"2127_CR144","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2018.197848","volume":"104","author":"J Bond","year":"2019","unstructured":"Bond J, Touzart A, Lepr\u00eatre S, Graux C, Bargetzi M, Lhermitte L, et al. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica. 2019;104:1617\u201325. https:\/\/doi.org\/10.3324\/haematol.2018.197848.","journal-title":"Haematologica"},{"key":"2127_CR145","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","volume":"119","author":"AFT Ribeiro","year":"2012","unstructured":"Ribeiro AFT, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119:5824\u201331. https:\/\/doi.org\/10.1182\/blood-2011-07-367961.","journal-title":"Blood"},{"key":"2127_CR146","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1078-0432.CCR-14-0327","volume":"21","author":"AR Sehgal","year":"2015","unstructured":"Sehgal AR, Gimotty PA, Zhao J, Hsu J-M, Daber R, Morrissette J, et al. DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin Cancer Res. 2015;21:1614\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0327.","journal-title":"Clin Cancer Res"},{"key":"2127_CR147","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/nm.4210","volume":"22","author":"OA Guryanova","year":"2016","unstructured":"Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016;22:1488\u201395. https:\/\/doi.org\/10.1038\/nm.4210.","journal-title":"Nat Med"},{"key":"2127_CR148","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood-2011-07-369934","volume":"119","author":"H-A Hou","year":"2012","unstructured":"Hou H-A, Kuo Y-Y, Liu C-Y, Chou W-C, Lee MC, Chen C-Y, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119:559\u201368. https:\/\/doi.org\/10.1182\/blood-2011-07-369934.","journal-title":"Blood"},{"key":"2127_CR149","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s43018-021-00213-9","volume":"2","author":"M Scheller","year":"2021","unstructured":"Scheller M, Ludwig AK, G\u00f6llner S, Rohde C, Kr\u00e4mer S, St\u00e4ble S, et al. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nat Cancer. 2021;2:527\u201344. https:\/\/doi.org\/10.1038\/s43018-021-00213-9.","journal-title":"Nat Cancer"},{"key":"2127_CR150","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","volume":"135","author":"MF Bezerra","year":"2020","unstructured":"Bezerra MF, Lima AS, Piqu\u00e9-Borr\u00e0s M-R, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135:870\u20135. https:\/\/doi.org\/10.1182\/blood.2019003339.","journal-title":"Blood"},{"key":"2127_CR151","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! targeting cancers with KRAS-G12D mutations. Trends Cancer. 2023;9:955\u201367. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.010.","journal-title":"Trends Cancer"},{"key":"2127_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2024.104248","volume":"135","author":"JH Rogers","year":"2024","unstructured":"Rogers JH, Rosen A, Reyes JM, Ketkar S, Conneely SE, Gupta R, et al. Dose-dependent effects of Dnmt3a in an inducible murine model of Kras-driven leukemia. Exp Hematol. 2024;135:104248. https:\/\/doi.org\/10.1016\/j.exphem.2024.104248.","journal-title":"Exp Hematol"},{"key":"2127_CR153","doi-asserted-by":"publisher","first-page":"18061","DOI":"10.1073\/pnas.1114946108","volume":"108","author":"Q Gao","year":"2011","unstructured":"Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D, et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci U S A. 2011;108:18061\u20136. https:\/\/doi.org\/10.1073\/pnas.1114946108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2127_CR154","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2016.04.018","volume":"97","author":"RE Husni","year":"2016","unstructured":"Husni RE, Shiba-Ishii A, Iiyama S, Shiozawa T, Kim Y, Nakagawa T, et al. DNMT3a expression pattern and its prognostic value in lung adenocarcinoma. Lung Cancer. 2016;97:59\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.018.","journal-title":"Lung Cancer"},{"key":"2127_CR155","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s43018-022-00361-6","volume":"3","author":"F Na","year":"2022","unstructured":"Na F, Pan X, Chen J, Chen X, Wang M, Chi P, et al. KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nat Cancer. 2022;3:753\u201367. https:\/\/doi.org\/10.1038\/s43018-022-00361-6.","journal-title":"Nat Cancer"},{"key":"2127_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96470-w","volume":"11","author":"X Yu","year":"2021","unstructured":"Yu X, Zhang Q, Gao F, Zhang M, Zheng Q, He Y, et al. Predictive value of m5C regulatory gene expression in pancreatic adenocarcinoma. Sci Rep. 2021;11:17529. https:\/\/doi.org\/10.1038\/s41598-021-96470-w.","journal-title":"Sci Rep"},{"key":"2127_CR157","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.2147\/CMAR.S201610","volume":"11","author":"W Jing","year":"2019","unstructured":"Jing W, Song N, Liu Y-P, Qu X-J, Qi Y-F, Li C, et al. DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer. Cancer Manag Res. 2019;11:6379\u201396. https:\/\/doi.org\/10.2147\/CMAR.S201610.","journal-title":"Cancer Manag Res"},{"key":"2127_CR158","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041578","volume":"104","author":"Z Wei","year":"2025","unstructured":"Wei Z, Kou Z, Luo Y, Cheng Y. DNA methyltransferase 3A: a prognostic biomarker and potential target for immunotherapy in gastric cancer. Medicine (Baltimore). 2025;104:e41578. https:\/\/doi.org\/10.1097\/MD.0000000000041578.","journal-title":"Medicine (Baltimore)"},{"key":"2127_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05657-8","volume":"14","author":"D Ye","year":"2023","unstructured":"Ye D, Wang Y, Deng X, Zhou X, Liu D, Zhou B, et al. DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP. Cell Death Dis. 2023;14:1\u201312. https:\/\/doi.org\/10.1038\/s41419-023-05657-8.","journal-title":"Cell Death Dis"},{"key":"2127_CR160","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321889","volume":"20","author":"S Yang","year":"2025","unstructured":"Yang S, Cheng M, Zhang S, Wang H, Wang J, Zhang X, et al. DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation. PLoS ONE. 2025;20:e0321889. https:\/\/doi.org\/10.1371\/journal.pone.0321889.","journal-title":"PLoS ONE"},{"key":"2127_CR161","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lungcan.2006.10.022","volume":"55","author":"R-K Lin","year":"2007","unstructured":"Lin R-K, Hsu H-S, Chang J-W, Chen C-Y, Chen J-T, Wang Y-C. Alteration of DNA methyltransferases contributes to 5\u2032CpG methylation and poor prognosis in lung cancer. Lung Cancer. 2007;55:205\u201313. https:\/\/doi.org\/10.1016\/j.lungcan.2006.10.022.","journal-title":"Lung Cancer"},{"key":"2127_CR162","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1038\/sj.onc.1205581","volume":"21","author":"M Sato","year":"2002","unstructured":"Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14ARF, p16INK4a and RASSF1A in human lung cancer cell lines. Oncogene. 2002;21:4822\u20139. https:\/\/doi.org\/10.1038\/sj.onc.1205581.","journal-title":"Oncogene"},{"key":"2127_CR163","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/mmr.2017.7923","volume":"17","author":"W Jing","year":"2018","unstructured":"Jing W, Song N, Liu Y, Qu X, Hou K, Yang X, et al. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells. Mol Med Rep. 2018;17:117\u201324. https:\/\/doi.org\/10.3892\/mmr.2017.7923.","journal-title":"Mol Med Rep"},{"key":"2127_CR164","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.1200\/JCO.2021.39.15_suppl.9113","volume":"39","author":"B Ricciuti","year":"2021","unstructured":"Ricciuti B, Alessi JVM, Li YY, Lawrence MN, Gupta H, Nishino M, et al. DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade. J Clin Oncol. 2021;39:9113\u20139113. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9113.","journal-title":"J Clin Oncol"},{"key":"2127_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018. https:\/\/doi.org\/10.3389\/fendo.2018.00402.","journal-title":"Front Endocrinol"},{"key":"2127_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.916725","volume":"10","author":"X Man","year":"2022","unstructured":"Man X, Li Q, Wang B, Zhang H, Zhang S, Li Z. DNMT3A and DNMT3B in breast tumorigenesis and potential therapy. Front Cell Dev Biol. 2022;10:916725. https:\/\/doi.org\/10.3389\/fcell.2022.916725.","journal-title":"Front Cell Dev Biol"},{"key":"2127_CR167","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221110668","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Zhen S, Tuo X, Chang S, Yang X, zhou Y, et al. Downregulation of DNMT3A attenuates the Warburg effect, proliferation, and invasion via promoting the inhibition of miR-603 on HK2 in ovarian cancer. Technol Cancer Res Treat. 2022;21:15330338221110668. https:\/\/doi.org\/10.1177\/15330338221110668.","journal-title":"Technol Cancer Res Treat"},{"key":"2127_CR168","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.3892\/or.2016.5134","volume":"36","author":"W Lu","year":"2016","unstructured":"Lu W, Lu T, Wei X. Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response. Oncol Rep. 2016;36:3597\u2013604. https:\/\/doi.org\/10.3892\/or.2016.5134.","journal-title":"Oncol Rep"},{"issue":"5","key":"2127_CR169","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202201703","volume":"6","author":"K Wang","year":"2023","unstructured":"Wang K, Gong D, Qiao X, Zheng J. MiR-532-3p inhibited the methylation of SOCS2 to suppress the progression of PC by targeting DNMT3A. Life Sci Alliance. 2023;6(5):202201703. https:\/\/doi.org\/10.26508\/lsa.202201703.","journal-title":"Life Sci Alliance"},{"key":"2127_CR170","doi-asserted-by":"publisher","first-page":"e1413","DOI":"10.1038\/cddis.2014.380","volume":"5","author":"F Yan","year":"2014","unstructured":"Yan F, Shen N, Pang J, Xie D, Deng B, Molina JR, et al. Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. Cell Death Dis. 2014;5:e1413\u2013e1413. https:\/\/doi.org\/10.1038\/cddis.2014.380.","journal-title":"Cell Death Dis"},{"key":"2127_CR171","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-17-1169","volume":"24","author":"T Liu","year":"2018","unstructured":"Liu T, Wu X, Chen T, Luo Z, Hu X. Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt\/\u03b2-catenin signaling. Clin Cancer Res. 2018;24:1748\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1169.","journal-title":"Clin Cancer Res"},{"key":"2127_CR172","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/cbin.11486","volume":"45","author":"X Han","year":"2021","unstructured":"Han X, Liu D, Zhou Y, Wang L, Hou H, Chen H, et al. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer. Cell Biol Int. 2021;45:227\u201337. https:\/\/doi.org\/10.1002\/cbin.11486.","journal-title":"Cell Biol Int"},{"key":"2127_CR173","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02319-z","volume":"41","author":"W Huang","year":"2022","unstructured":"Huang W, Li H, Yu Q, Xiao W, Wang DO. LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Exp Clin Cancer Res. 2022;41:100. https:\/\/doi.org\/10.1186\/s13046-022-02319-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"2127_CR174","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317732181","volume":"39","author":"A Ponciano-G\u00f3mez","year":"2017","unstructured":"Ponciano-G\u00f3mez A, Mart\u00ednez-Tovar A, Vela-Ojeda J, Olarte-Carrillo I, Centeno-Cruz F, Garrido E. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia. Tumour Biol. 2017;39:1010428317732181. https:\/\/doi.org\/10.1177\/1010428317732181.","journal-title":"Tumour Biol"},{"key":"2127_CR175","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01091-5","volume":"14","author":"SX Yang","year":"2021","unstructured":"Yang SX, Hollingshead M, Rubinstein L, Nguyen D, Larenjeira ABA, Kinders RJ, et al. TET2 and DNMT3A mutations and exceptional response to 4\u2032-thio-2\u2032-deoxycytidine in human solid tumor models. J Hematol Oncol. 2021;14:83. https:\/\/doi.org\/10.1186\/s13045-021-01091-5.","journal-title":"J Hematol Oncol"},{"key":"2127_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03288-3","volume":"24","author":"T Cheng","year":"2024","unstructured":"Cheng T, Zhou C, Bian S, Sobeck K, Liu Y. Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma. Cancer Cell Int. 2024;24:110. https:\/\/doi.org\/10.1186\/s12935-024-03288-3.","journal-title":"Cancer Cell Int"},{"key":"2127_CR177","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.freeradbiomed.2024.04.222","volume":"219","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yimamu M, Cheng Z, Ji J, Wu L, Feng J, et al. TRIM47-CDO1 axis dictates hepatocellular carcinoma progression by modulating ferroptotic cell death through the ubiquitin\u2012proteasome system. Free Radic Biol Med. 2024;219:31\u201348. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.04.222.","journal-title":"Free Radic Biol Med"},{"key":"2127_CR178","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1620\/tjem.232.187","volume":"232","author":"Y Yang","year":"2014","unstructured":"Yang Y, Fan Y-C, Gao S, Dou C-Y, Zhang J-J, Sun F-K, et al. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Tohoku J Exp Med. 2014;232:187\u201394. https:\/\/doi.org\/10.1620\/tjem.232.187.","journal-title":"Tohoku J Exp Med"},{"key":"2127_CR179","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Behdarvand Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M, et al. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy. Mol Cancer. 2023;22:189. https:\/\/doi.org\/10.1186\/s12943-023-01873-0.","journal-title":"Mol Cancer"},{"key":"2127_CR180","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/stem.2655","volume":"35","author":"J-H Lee","year":"2017","unstructured":"Lee J-H, Salci KR, Reid JC, Orlando L, Tanasijevic B, Shapovalova Z, et al. Brief report: human acute myeloid leukemia reprogramming to pluripotency is a rare event and selects for patient hematopoietic cells devoid of leukemic mutations. Stem Cells. 2017;35:2095\u2013102. https:\/\/doi.org\/10.1002\/stem.2655.","journal-title":"Stem Cells"},{"key":"2127_CR181","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jmcb\/mjr028","volume":"3","author":"A Mattout","year":"2011","unstructured":"Mattout A, Biran A, Meshorer E. Global epigenetic changes during somatic cell reprogramming to iPS cells. J Mol Cell Biol. 2011;3:341\u201350. https:\/\/doi.org\/10.1093\/jmcb\/mjr028.","journal-title":"J Mol Cell Biol"},{"key":"2127_CR182","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/stcltm\/szad022","volume":"12","author":"D Golubeva","year":"2023","unstructured":"Golubeva D, Porras DP, Doyle M, Reid JC, Tanasijevic B, Boyd AL, et al. Reprogramming of acute myeloid leukemia patients cells: harboring cancer mutations requires targeting of AML hierarchy. Stem Cells Transl Med. 2023;12:334\u201354. https:\/\/doi.org\/10.1093\/stcltm\/szad022.","journal-title":"Stem Cells Transl Med"},{"key":"2127_CR183","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-023-00433-y","volume":"12","author":"Z Fang","year":"2023","unstructured":"Fang Z, Li P, Du F, Shang L, Li L. The role of organoids in cancer research. Exp Hematol Oncol. 2023;12:69. https:\/\/doi.org\/10.1186\/s40164-023-00433-y.","journal-title":"Exp Hematol Oncol"},{"key":"2127_CR184","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024;5:1351\u201377. https:\/\/doi.org\/10.1016\/j.medj.2024.08.010.","journal-title":"Med"},{"key":"2127_CR185","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"key":"2127_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1146738","volume":"14","author":"J Su","year":"2023","unstructured":"Su J, Zhou L, Zhang Z, Xiao X, Qin Y, Zhou X, et al. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma. Front Immunol. 2023;14:1146738. https:\/\/doi.org\/10.3389\/fimmu.2023.1146738.","journal-title":"Front Immunol"},{"key":"2127_CR187","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11307-022-01795-1","volume":"25","author":"P Siminzar","year":"2023","unstructured":"Siminzar P, Tohidkia MR, Eppard E, Vahidfar N, Tarighatnia A, Aghanejad A. Recent trends in diagnostic biomarkers of tumor microenvironment. Mol Imaging Biol. 2023;25:464\u201382. https:\/\/doi.org\/10.1007\/s11307-022-01795-1.","journal-title":"Mol Imaging Biol"},{"key":"2127_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18:59. https:\/\/doi.org\/10.1186\/s12964-020-0530-4.","journal-title":"Cell Commun Signal"},{"key":"2127_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753.","journal-title":"Pharmacol Ther"},{"key":"2127_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00168-1","volume":"5","author":"GE Wensink","year":"2021","unstructured":"Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF, Kranenburg OW, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. npj Precis Oncol. 2021;5:30. https:\/\/doi.org\/10.1038\/s41698-021-00168-1.","journal-title":"npj Precis Oncol"},{"key":"2127_CR191","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","volume":"188","author":"K Agrawal","year":"2018","unstructured":"Agrawal K, Das V, Vyas P, Hajd\u00fach M. Nucleosidic DNA demethylating epigenetic drugs \u2013 a comprehensive review from discovery to clinic. Pharmacol Ther. 2018;188:45\u201379. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.02.006.","journal-title":"Pharmacol Ther"},{"key":"2127_CR192","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00280-007-0531-7","volume":"61","author":"AF Cashen","year":"2008","unstructured":"Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharmacokinetics of Decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol. 2008;61:759\u201366. https:\/\/doi.org\/10.1007\/s00280-007-0531-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2127_CR193","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Pazdur R. FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza\u2122) for injectable suspension. Oncologist. 2005;10:176\u201382. https:\/\/doi.org\/10.1634\/theoncologist.10-3-176.","journal-title":"Oncologist"},{"key":"2127_CR194","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","volume":"19","author":"RZ Mahfouz","year":"2013","unstructured":"Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, et al. Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or Decitabine therapy. Clin Cancer Res. 2013;19:938\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1722.","journal-title":"Clin Cancer Res"},{"key":"2127_CR195","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0091270004271947","volume":"45","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of Azacitidine subcutaneous versus intravenous in patients with the Myelodysplastic Syndromes. J Clin Pharmacol. 2005;45:597\u2013602. https:\/\/doi.org\/10.1177\/0091270004271947.","journal-title":"J Clin Pharmacol"},{"key":"2127_CR196","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/nar\/gkq187","volume":"38","author":"K Patel","year":"2010","unstructured":"Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2\u2032-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 2010;38:4313\u201324. https:\/\/doi.org\/10.1093\/nar\/gkq187.","journal-title":"Nucleic Acids Res"},{"key":"2127_CR197","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/a:1011946030404","volume":"15","author":"CM Bender","year":"1998","unstructured":"Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. Pharm Res. 1998;15:175\u201387. https:\/\/doi.org\/10.1023\/a:1011946030404.","journal-title":"Pharm Res"},{"key":"2127_CR198","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1073\/pnas.0501034102","volume":"102","author":"O Mortusewicz","year":"2005","unstructured":"Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt H. Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl Acad Sci U S A. 2005;102:8905\u20139. https:\/\/doi.org\/10.1073\/pnas.0501034102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2127_CR199","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1158\/1078-0432.CCR-13-1453","volume":"20","author":"TE Fandy","year":"2014","unstructured":"Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res. 2014;20:1249\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1453.","journal-title":"Clin Cancer Res"},{"key":"2127_CR200","doi-asserted-by":"publisher","first-page":"18736","DOI":"10.1074\/jbc.M114.563650","volume":"289","author":"S Poirier","year":"2014","unstructured":"Poirier S, Samami S, Mamarbachi M, Demers A, Chang TY, Vance DE, et al. The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism. J Biol Chem. 2014;289:18736\u201351. https:\/\/doi.org\/10.1074\/jbc.M114.563650.","journal-title":"J Biol Chem"},{"key":"2127_CR201","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","volume":"38","author":"EA Griffiths","year":"2013","unstructured":"Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR. SGI-110: DNA methyltransferase inhibitor oncolytic. Drugs Future. 2013;38:535\u201343.","journal-title":"Drugs Future"},{"key":"2127_CR202","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-014-2503-z","volume":"74","author":"JV Thottassery","year":"2014","unstructured":"Thottassery JV, Sambandam V, Allan PW, Maddry JA, Maxuitenko YY, Tiwari K, et al. Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4\u2032-thio-2\u2032-deoxycytidine and 5-aza-4\u2032-thio-2\u2032-deoxycytidine. Cancer Chemother Pharmacol. 2014;74:291\u2013302. https:\/\/doi.org\/10.1007\/s00280-014-2503-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2127_CR203","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1182\/bloodadvances.2023010179","volume":"7","author":"P Fenaux","year":"2023","unstructured":"Fenaux P, Gobbi M, Kropf PL, Issa J-PJ, Roboz GJ, Mayer J, et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023;7:5027\u201337. https:\/\/doi.org\/10.1182\/bloodadvances.2023010179.","journal-title":"Blood Adv"},{"key":"2127_CR204","doi-asserted-by":"publisher","first-page":"TPS7077","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7077","volume":"40","author":"P Vachhani","year":"2022","unstructured":"Vachhani P, Murthy GSG, Jamy O, Bachiashvili K, Rangaraju S, Cole T, et al. A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress). J Clin Oncol. 2022;40:TPS7077. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS7077.","journal-title":"J Clin Oncol"},{"key":"2127_CR205","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41408-022-00664-y","volume":"12","author":"B Lim","year":"2022","unstructured":"Lim B, Yoo D, Chun Y, Go A, Cho K-J, Choi D, et al. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia. Blood Cancer J. 2022;12:57. https:\/\/doi.org\/10.1038\/s41408-022-00664-y.","journal-title":"Blood Cancer J"},{"key":"2127_CR206","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1158\/1078-0432.CCR-23-2368","volume":"30","author":"Y Wang","year":"2024","unstructured":"Wang Y, Situ X, Cardenas H, Siu E, Alhunayan SA, Keathley R, et al. Preclinical evaluation of NTX-301, a novel DNA hypomethylating agent in ovarian cancer. Clin Cancer Res. 2024;30:1175\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2368.","journal-title":"Clin Cancer Res"},{"key":"2127_CR207","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/17501911.2025.2557179","volume":"17","author":"J Cheng","year":"2025","unstructured":"Cheng J, O\u2019Connell C. Novel approaches to the use of hypomethylating agents in myeloid malignancies. Epigenomics. 2025;17:1201\u201312. https:\/\/doi.org\/10.1080\/17501911.2025.2557179.","journal-title":"Epigenomics"},{"key":"2127_CR208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-04139-5","volume":"5","author":"B Bhogal","year":"2022","unstructured":"Bhogal B, Weir BA, Crescenzo R, Marien A, Kwon MC, Philippar U, et al. The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation. Commun Biol. 2022;5:1\u201313. https:\/\/doi.org\/10.1038\/s42003-022-04139-5.","journal-title":"Commun Biol"},{"key":"2127_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021;13:166. https:\/\/doi.org\/10.1186\/s13148-021-01154-x.","journal-title":"Clin Epigenetics"},{"key":"2127_CR210","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","volume":"10","author":"S Moufarrij","year":"2020","unstructured":"Moufarrij S, Srivastava A, Gomez S, Hadley M, Palmer E, Austin PT, et al. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci Rep. 2020;10:3470. https:\/\/doi.org\/10.1038\/s41598-020-60409-4.","journal-title":"Sci Rep"},{"key":"2127_CR211","doi-asserted-by":"publisher","first-page":"746","DOI":"10.18632\/oncotarget.2685","volume":"6","author":"O Gayet","year":"2014","unstructured":"Gayet O, Loncle C, Duconseil P, Gilabert M, Lopez MB, Moutardier V, et al. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget. 2014;6:746\u201354. https:\/\/doi.org\/10.18632\/oncotarget.2685.","journal-title":"Oncotarget"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02127-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02127-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02127-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:14:43Z","timestamp":1780013683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02127-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":211,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02127-8","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}